Literature DB >> 20427654

Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Pradeep Kurup1, Yongfang Zhang, Jian Xu, Deepa V Venkitaramani, Vahram Haroutunian, Paul Greengard, Angus C Nairn, Paul J Lombroso.   

Abstract

Amyloid beta (Abeta) is involved in the etiology of Alzheimer's disease (AD) and may contribute to cognitive deficits by increasing internalization of ionotropic glutamate receptors. Striatal-enriched protein tyrosine phosphatase 61 (STEP(61)), which is targeted in part to the postsynaptic terminal, has been implicated in this process. Here we show that STEP(61) levels are progressively increased in the cortex of Tg2576 mice over the first year, as well as in prefrontal cortex of human AD brains. The increased STEP(61) was associated with greater STEP activity, dephosphorylation of phospho-tyr(1472) of the NR2B subunit, and decreased NR1 and NR2B subunits on neuronal membranes. Treatment with Abeta-enriched medium also increased STEP(61) levels and decreased NR1/NR2B abundance in mouse cortical cultures as determined by biotinylation experiments. In STEP knock-out cultures, Abeta treatment failed to induce NMDA receptor internalization. The mechanism for the increase in STEP(61) levels appears to involve the ubiquitin proteasome system. Blocking the proteasome resulted in elevated levels of STEP(61). Moreover, STEP(61)-ubiquitin conjugates were increased in wild-type cortical slices upon Abeta treatment as well as in 12 month Tg2576 cortex. These findings reveal a novel mechanism by which Abeta-mediated accumulation of STEP(61) results in increased internalization of NR1/NR2B receptor that may contribute to the cognitive deficits in AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427654      PMCID: PMC2868326          DOI: 10.1523/JNEUROSCI.0157-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  53 in total

1.  Amyloid peptide attenuates the proteasome activity in neuronal cells.

Authors:  Sangsoo Oh; Hyun Seok Hong; Enmi Hwang; Hae Jin Sim; Woojin Lee; Su Jeon Shin; Inhee Mook-Jung
Journal:  Mech Ageing Dev       Date:  2005-09-08       Impact factor: 5.432

2.  Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.

Authors:  Claudia G Almeida; Reisuke H Takahashi; Gunnar K Gouras
Journal:  J Neurosci       Date:  2006-04-19       Impact factor: 6.167

3.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  J Steven Jacobsen; Chi-Cheng Wu; Jeffrey M Redwine; Thomas A Comery; Robert Arias; Mark Bowlby; Robert Martone; John H Morrison; Menelas N Pangalos; Peter H Reinhart; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

4.  Ubiquitin is a component of paired helical filaments in Alzheimer's disease.

Authors:  H Mori; J Kondo; Y Ihara
Journal:  Science       Date:  1987-03-27       Impact factor: 47.728

Review 5.  Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.

Authors:  F M S de Vrij; D F Fischer; F W van Leeuwen; E M Hol
Journal:  Prog Neurobiol       Date:  2004-12       Impact factor: 11.685

6.  Regulation of NMDA receptor trafficking by amyloid-beta.

Authors:  Eric M Snyder; Yi Nong; Claudia G Almeida; Surojit Paul; Timothy Moran; Eun Young Choi; Angus C Nairn; Michael W Salter; Paul J Lombroso; Gunnar K Gouras; Paul Greengard
Journal:  Nat Neurosci       Date:  2005-07-17       Impact factor: 24.884

7.  Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease.

Authors:  Jeannie Chin; Jorge J Palop; Jukka Puoliväli; Catherine Massaro; Nga Bien-Ly; Hilary Gerstein; Kimberly Scearce-Levie; Eliezer Masliah; Lennart Mucke
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

8.  Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts.

Authors:  C Anthony Altar; Linda W Jurata; Vin Charles; Andrew Lemire; Peng Liu; Yury Bukhman; Theresa A Young; Jeff Bullard; Hiroko Yokoe; Maree J Webster; Michael B Knable; Jeffrey A Brockman
Journal:  Biol Psychiatry       Date:  2005-07-15       Impact factor: 13.382

9.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

10.  Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease.

Authors:  V Haroutunian; D P Perl; D P Purohit; D Marin; K Khan; M Lantz; K L Davis; R C Mohs
Journal:  Arch Neurol       Date:  1998-09
View more
  106 in total

1.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  In vitro stretch injury induces time- and severity-dependent alterations of STEP phosphorylation and proteolysis in neurons.

Authors:  Mahlet N Mesfin; Catherine R von Reyn; Rosalind E Mott; Mary E Putt; David F Meaney
Journal:  J Neurotrauma       Date:  2012-06-25       Impact factor: 5.269

3.  A STEP forward in neural function and degeneration.

Authors:  Matthew L Baum; Pradeep Kurup; Jian Xu; Paul J Lombroso
Journal:  Commun Integr Biol       Date:  2010-09

4.  Oxidative stress-induced oligomerization inhibits the activity of the non-receptor tyrosine phosphatase STEP61.

Authors:  Ishani Deb; Ranjana Poddar; Surojit Paul
Journal:  J Neurochem       Date:  2011-01-19       Impact factor: 5.372

Review 5.  The upside of APP at synapses.

Authors:  Hyang-Sook Hoe; Hey-Kyoung Lee; Daniel T S Pak
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

6.  Down-regulation of BDNF in cell and animal models increases striatal-enriched protein tyrosine phosphatase 61 (STEP61 ) levels.

Authors:  Jian Xu; Pradeep Kurup; Garikoitz Azkona; Tyler D Baguley; Ana Saavedra; Angus C Nairn; Jonathan A Ellman; Esther Pérez-Navarro; Paul J Lombroso
Journal:  J Neurochem       Date:  2015-09-17       Impact factor: 5.372

Review 7.  Taking STEPs forward to understand fragile X syndrome.

Authors:  Susan M Goebel-Goody; Paul J Lombroso
Journal:  Results Probl Cell Differ       Date:  2012

8.  Inhibition of striatal-enriched tyrosine phosphatase 61 in the dorsomedial striatum is sufficient to increased ethanol consumption.

Authors:  Emmanuel Darcq; Sami Ben Hamida; Su Wu; Khanky Phamluong; Viktor Kharazia; Jian Xu; Paul Lombroso; Dorit Ron
Journal:  J Neurochem       Date:  2014-03-27       Impact factor: 5.372

Review 9.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Inhibition of striatal-enriched protein tyrosine phosphatase (STEP) activity reverses behavioral deficits in a rodent model of autism.

Authors:  Manavi Chatterjee; Priya Singh; Jian Xu; Paul J Lombroso; Pradeep K Kurup
Journal:  Behav Brain Res       Date:  2020-05-24       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.